Follicular Thyroid Carcinoma: Understanding Your Pathology Report

by Jason Wasserman MD PhD FRCPC
April 20, 2026

Follicular thyroid carcinoma is a type of thyroid cancer that starts from follicular cells, the cells that normally make thyroid hormone. The thyroid is a butterfly-shaped gland at the front of the neck that helps regulate metabolism, heart rate, and body temperature.

Follicular thyroid carcinoma is a well-differentiated cancer, meaning the tumor cells still look a lot like normal thyroid cells under the microscope. In fact, they look almost identical to the cells of a non-cancerous thyroid tumor called a follicular adenoma. What makes follicular thyroid carcinoma a cancer rather than a benign tumor is invasion — tumor cells have grown through the thin layer of tissue that surrounds the tumor (called the tumor capsule), or have entered nearby blood vessels.

How common is follicular thyroid carcinoma?

Follicular thyroid carcinoma accounts for approximately 5 to 15 percent of all thyroid cancers. It is much less common than papillary thyroid carcinoma and is more often seen in adults than in children. It is more common in parts of the world with low iodine intake.

What are the symptoms of follicular thyroid carcinoma?

Most people first notice a painless lump in the front of the neck. Some tumors are found by chance during imaging tests performed for another reason, or during a routine physical examination.

Larger tumors can press on nearby structures, causing symptoms such as difficulty swallowing, hoarseness, or a sensation of pressure in the neck. Most patients have normal thyroid hormone levels, so symptoms of an overactive or underactive thyroid are uncommon.

In a small number of cases, follicular thyroid carcinoma has already spread to distant parts of the body (most often to the bones or lungs) by the time it is diagnosed. When this happens, the first symptoms may come from the site of spread — for example, bone pain or shortness of breath.

What causes follicular thyroid carcinoma?

The exact cause of follicular thyroid carcinoma is not always known. Known risk factors include low dietary iodine intake and previous radiation exposure, especially during childhood.

Most cases happen by chance and are not inherited. However, a small number are associated with inherited tumor syndromes, including PTEN hamartoma tumor syndrome (Cowden syndrome), DICER1 syndrome, Werner syndrome, and Carney complex. If an inherited syndrome is suspected, genetic counseling and testing may be recommended for you and your family members.

How is the diagnosis of follicular thyroid carcinoma made?

The diagnosis of follicular thyroid carcinoma usually begins when a thyroid nodule is found during a physical exam or on imaging tests such as ultrasound. A fine needle aspiration (FNA) biopsy is often performed next, in which a thin needle is used to remove a small sample of cells from the nodule. An FNA can show that the nodule is made up of follicular cells, but it cannot confirm the diagnosis of follicular thyroid carcinoma on its own. This is because follicular thyroid carcinoma and benign follicular adenoma are composed of cells that look almost identical; the difference lies in whether tumor cells invade the capsule or enter blood vessels, and this can only be assessed when the entire tumor is removed and examined under the microscope. For this reason, FNA results in this setting are usually reported as “follicular neoplasm” or “suspicious for follicular neoplasm,” and surgery is needed to make the final diagnosis. After surgery, the pathologist examines the tumor and its capsule in full to look for invasion. Immunohistochemistry is sometimes used to confirm that the tumor started from thyroid follicular cells; in follicular thyroid carcinoma, the tumor cells typically stain for thyroglobulin, TTF-1, and PAX8. Imaging is used before or after surgery to check for spread to lymph nodes in the neck or to distant parts of the body.

What does follicular thyroid carcinoma look like under the microscope?

Under the microscope, follicular thyroid carcinoma is made up of follicular cells arranged in small round structures called follicles (similar to those in normal thyroid tissue) or in solid sheets or long cords. The tumor cells themselves look very similar to those of a benign follicular adenoma. The key features that identify the tumor as cancer are capsular invasion and vascular invasion.

Capsular invasion. Tumor cells have grown through the tumor capsule (the thin layer of tissue that separates the tumor from the surrounding normal thyroid). The tumor cells must completely breach the capsule; cells that only push into the capsule without crossing it are not enough.
Vascular invasion. Tumor cells are seen inside blood vessels located in or just outside the tumor capsule. Typically, the tumor cells are attached to the vessel wall or are mixed with a blood clot. Blood vessels act like highways, carrying tumor cells to distant parts of the body.

At least one focus of capsular or vascular invasion is required to make the diagnosis of follicular thyroid carcinoma. The amount and pattern of invasion are used to classify the tumor into one of the subtypes described below.

Subtypes of follicular thyroid carcinoma

Follicular thyroid carcinoma is divided into three subtypes based on the extent of invasion. Subtype is one of the most important pieces of information in the pathology report because it strongly influences the risk of recurrence, the risk of spread to distant sites, and the intensity of treatment and follow-up recommended.

Minimally invasive follicular thyroid carcinoma

Minimally invasive tumors show capsular invasion only — the tumor cells have broken through the capsule but have not entered any blood vessels. These tumors usually behave in a very indolent manner (slow-growing and non-aggressive). When the tumor is completely removed by surgery, the outcome is excellent, and additional treatment such as radioactive iodine is often not required.

Encapsulated angioinvasive follicular thyroid carcinoma

These tumors are surrounded by a capsule but show vascular invasion — tumor cells have entered one or more blood vessels. Because blood vessels can carry tumor cells to distant parts of the body, these tumors carry a higher risk of spread than minimally invasive tumors. The pathologist further divides vascular invasion into:

Limited (focal) vascular invasion. Tumor cells are seen in fewer than 4 blood vessels. The risk of recurrence and distant spread is intermediate.
Extensive vascular invasion. Tumor cells are seen in 4 or more blood vessels. The risk of recurrence and distant spread is higher, and closer follow-up is usually recommended.

Widely invasive follicular thyroid carcinoma

Widely invasive tumors show extensive growth into the surrounding normal thyroid tissue or into nearby soft tissues of the neck. The tumor capsule is often incomplete or absent, making the invasion easy to see. These tumors commonly involve multiple blood vessels and carry the highest risk of recurrence and distant spread of the three subtypes.

Biomarkers in follicular thyroid carcinoma

Biomarkers are molecular features of a tumor that can help explain how it developed, how it may behave, and, in some cases, how it may respond to treatment. Biomarker testing is not performed on every follicular thyroid carcinoma; it is most often used for larger or more advanced tumors, when the diagnosis is uncertain, or when an inherited syndrome is suspected. The biomarkers most relevant to follicular thyroid carcinoma are described below.

RAS mutations

The RAS family of genes (HRAS, KRAS, and NRAS) makes proteins that help control cell growth. Mutations in these genes are the most common molecular change in follicular thyroid carcinoma. RAS-mutated tumors tend to grow in a follicular pattern and may be slightly more likely to spread through the bloodstream to distant sites than through lymph nodes. RAS mutations are also found in benign follicular adenomas and in some other thyroid tumors, so they are not specific for cancer.

PAX8::PPARG fusion

A fusion happens when part of one gene becomes joined to part of another, creating an abnormal combined gene. In some follicular thyroid carcinomas, a fusion forms between PAX8 and PPARG. Tumors with this fusion are often seen in younger patients and tend to behave less aggressively than other follicular thyroid carcinomas, although there are exceptions.

TERT promoter mutations

The TERT promoter is a region of DNA that controls how much telomerase a cell produces. Telomerase helps cells maintain their chromosomes’ integrity during cell division. Mutations in the TERT promoter allow tumor cells to divide indefinitely. In thyroid cancer, TERT promoter mutations are associated with a higher risk of recurrence and distant spread, especially when they occur together with a RAS mutation. There is no drug that directly targets TERT, but the presence of this mutation often influences how intensively the cancer is treated and how closely it is followed.

PTEN mutations

The PTEN gene normally helps slow down cell growth. Inherited changes in PTEN cause PTEN hamartoma tumor syndrome (also known as Cowden syndrome), which increases the risk of several cancers, including follicular thyroid carcinoma, breast cancer, and endometrial cancer. If a PTEN mutation is found in your tumor, additional testing on a blood sample may be recommended to determine whether the change is inherited. A germline (inherited) PTEN mutation has important implications for both you and your family members.

DICER1 mutations

The DICER1 gene helps control how other genes are switched on and off. Inherited changes in DICER1 cause DICER1 syndrome, which increases the risk of several tumors, including thyroid cancer (often at a young age), pleuropulmonary blastoma (a rare lung tumor), and certain ovarian tumors. As with PTEN, a finding of a DICER1 mutation in the tumor may prompt testing for an inherited cause.

Tumor size

After the thyroid is removed, the tumor is measured in three dimensions, and the largest measurement is reported. Tumor size is one of the main factors used to determine the pathologic tumor stage (pT). Larger tumors are more likely to have grown beyond the thyroid and more likely to have spread to distant parts of the body.

Extrathyroidal extension

Extrathyroidal extension means the cancer has spread beyond the thyroid gland into surrounding tissue. Follicular thyroid carcinoma less commonly shows extrathyroidal extension than some other thyroid cancers, but when it is present, it may be described as:

Microscopic extrathyroidal extension. Small amounts of tumor growth just beyond the thyroid that can only be seen under the microscope.
Gross (macroscopic) extrathyroidal extension. Tumor growth clearly visible during surgery or on imaging, extending into nearby structures such as the neck muscles, voice box (larynx), windpipe (trachea), or food pipe (esophagus).

Gross extrathyroidal extension increases the pathologic tumor stage and is usually associated with a higher risk of recurrence.

Lymph nodes

Lymph nodes are small immune organs that filter a fluid called lymph. Cancer cells can spread from the thyroid to nearby lymph nodes through lymphatic channels. Unlike papillary thyroid carcinoma, follicular thyroid carcinoma rarely spreads to lymph nodes; it more often spreads through the bloodstream to distant sites such as the bones or lungs.

If lymph nodes are removed during surgery, the pathologist examines them under the microscope and reports the total number of lymph nodes examined and the number, if any, that contain cancer cells. Finding cancer in a lymph node raises the nodal stage (pN) and may influence recommendations for additional treatment and follow-up.

Margins

A margin is the edge of the tissue removed during surgery. The pathologist examines the margins to determine whether any cancer cells extend to the cut edge.

Negative margin. No cancer cells are seen at the edge. This suggests the tumor was completely removed.
Positive margin. Cancer cells are seen at the edge. This means some tumor may remain in the body, and additional treatment may be needed.

Pathologic stage (pTNM)

The pathologic stage for follicular thyroid carcinoma is based on the tumor size and extent (pT), whether cancer is found in nearby lymph nodes (pN), and whether the cancer has spread to distant parts of the body (pM). Most pathology reports include details for pT and pN.

Tumor stage (pT)

T1: Tumor 2 cm or smaller and still within the thyroid.
- T1a: Tumor 1 cm or smaller.
- T1b: Tumor larger than 1 cm but not larger than 2 cm.
T2: Tumor larger than 2 cm but not larger than 4 cm and still within the thyroid.
T3: Tumor larger than 4 cm, or with early growth into the muscles around the thyroid.
- T3a: Tumor larger than 4 cm but still within the thyroid.
- T3b: Tumor of any size with gross extrathyroidal extension into the strap muscles (the muscles just in front of the thyroid).
T4: Tumor with more extensive growth outside the thyroid.
- T4a: Tumor growing into the soft tissues under the skin, voice box, windpipe, food pipe, or nearby nerves.
- T4b: Tumor growing into the tissue at the front of the spine or surrounding major blood vessels in the neck or chest.

Nodal stage (pN)

NX: No lymph nodes were submitted for examination.
N0: No cancer was found in any of the lymph nodes examined.
N1: Cancer was found in one or more lymph nodes.
- N1a: Cancer in lymph nodes in the central part of the neck, around the thyroid.
- N1b: Cancer in lymph nodes on the side of the neck or in the upper chest.

What happens after the diagnosis?

After the diagnosis has been confirmed, your healthcare team will review your pathology report, imaging studies, and thyroid blood tests to plan treatment. This team may include an endocrinologist, a thyroid surgeon, a nuclear medicine specialist, a radiation oncologist, and a medical oncologist.

Most patients are treated with surgery to remove part or all of the thyroid. Depending on tumor size, subtype, extent of invasion, and biomarker findings, additional treatments may include radioactive iodine, thyroid hormone suppression therapy, external-beam radiation, or, in rare advanced cases, targeted drug therapy.

The outlook for follicular thyroid carcinoma depends mainly on the subtype and the extent of invasion. Minimally invasive tumors have an excellent outcome after surgery. Encapsulated angioinvasive tumors with limited vascular invasion still do well with appropriate treatment, while those with extensive vascular invasion or widely invasive disease carry a higher risk of recurrence and distant spread. The presence of distant metastases and certain biomarkers, such as TERT promoter mutations, is also associated with worse outcomes.

After treatment, regular follow-up is needed to watch for any signs that the cancer has returned. This usually includes blood tests (including thyroglobulin in most cases), neck ultrasound or other imaging, and clinical examinations. Most patients who have had their entire thyroid removed will need to take thyroid hormone replacement for the rest of their lives.

Questions to ask your doctor

What subtype of follicular thyroid carcinoma do I have — minimally invasive, encapsulated angioinvasive, or widely invasive?
Was capsular invasion, vascular invasion, or both present in my tumor?
If vascular invasion was present, was it limited or extensive?
Did the cancer grow beyond the thyroid (extrathyroidal extension)?
Were the surgical margins negative?
Were any lymph nodes involved?
Were any biomarkers, such as RAS, PAX8::PPARG, or TERT, tested? Do the results change my treatment?
Could my cancer be part of an inherited syndrome? Should I see a genetic counselor?
Will I need radioactive iodine therapy?
What is my risk of the cancer coming back?
How often will I need follow-up visits, blood tests, and imaging?